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Abstract 
Background: Castrate resistant prostate cancer (CRPC) is often driven by constitutively active forms of the androgen 
receptor such as the V7 splice variant (AR-V7) and commonly becomes resistant to established hormonal therapy 
strategies such as enzalutamide as a result. The lysine demethylase LSD1 is a co-activator of the wild type androgen 
receptor and a potential therapeutic target in hormone sensitive prostate cancer. We evaluated whether LSD1 could 
also be therapeutically targeted in CRPC models driven by AR-V7.
Methods: We utilised cell line models of castrate resistant prostate cancer through over expression of AR-V7 to test 
the impact of chemical LSD1 inhibition on AR activation. We validated findings through depletion of LSD1 expression 
and in prostate cancer cell lines that express AR-V7.
Results: Chemical inhibition of LSD1 resulted in reduced activation of the androgen receptor through both the wild 
type and its AR-V7 splice variant forms. This was confirmed and validated in luciferase reporter assays, in LNCaP and 
22Rv1 prostate cancer cell lines and in LSD1 depletion experiments.
Conclusion: LSD1 contributes to activation of both the wild type and V7 splice variant forms of the androgen recep-
tor and can be therapeutically targeted in models of CRPC. Further development of this approach is warranted.
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Background
Over 40,000 men are diagnosed with prostate cancer, and 
over 10,000 die from advanced metastatic disease, annu-
ally in the UK. Initial treatment of metastatic disease is 
reliant on inhibiting androgen receptor (AR) signalling by 
systemic androgen deprivation therapy (ADT). Although 
almost all patients respond to ADT, disease progression, 
to a clinical phenotype termed castration resistant pros-
tate cancer (CRPC), occurs in virtually all patients. Meta-
static CRPC is almost uniformly lethal within a median of 
2–3  years and is commonly accompanied by significant 
symptomatic and healthcare burden [1].
Treatment options after transition to CRPC have devel-
oped significantly in the last few years. Approaches that 
are established to extend survival include further hor-
monal intervention with either the new generation AR 
antagonist enzalutamide or the CYP17A1 androgen syn-
thesis inhibitor abiraterone acetate [2–5]. These thera-
peutic advances reflect the fact that, despite resistance to 
systemic androgen suppression, CRPC usually remains 
critically dependent on AR signalling.
As a conventional nuclear steroid hormone receptor 
transcription factor, AR activation involves ligand bind-
ing (e.g., testosterone, dihydro-testosterone), phospho-
rylation and homo-dimerisation, nuclear translocation, 
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formation of co-regulator complex interactions with 
chromatin modifiers, androgen response element (ARE) 
sequence binding within target gene promoters and AR 
target gene expression and suppression. Non-genomic/
non-ARE mediated effects also occur through AR activa-
tion [6].
Androgen deprivation therapy failure and transition to 
CRPC occurs through multiple mechanisms including 
expression of constitutively active AR point mutants and 
splice variants, AR co-regulator expression changes, AR 
expression change, altered AR ligand sensitivity/promis-
cuity and signalling pathway crosstalk (e.g., with PI3K/
AKT or IGFR). Critically we have no current routinely 
available means within the clinic to detect resistance 
mechanisms to either initial ADT or subsequent thera-
pies [6–12].
Intense interest currently surrounds the V7 splice 
variant of the AR which lacks a ligand (or enzalutamide) 
binding domain leaving a constitutively active N-termi-
nal. AR-V7 expression represents a relatively common 
cause of transition to a CRPC phenotype and a cause of 
resistance to enzalutamide or abiraterone. Recent data 
found that AR-V7 detection in circulating tumour cells 
was possible in 19–39% of CRPC patients who were naive 
to new generation hormonal agents. AR-V7 expression 
was associated with almost complete loss of biochemi-
cal prostate specific antigen (PSA) response to enzaluta-
mide or abiraterone and reduced median survival [7, 8]. 
Subsequent data have emerged to indicate that AR-V7 
forms part of a wider spectrum of activating AR struc-
tural derangements, typically splice variants and point 
mutants, that drive some CRPC and with the hope that 
detection might allow for treatment resistance/sensitivity 
biomarkers to be developed [13].
Co-regulators of AR transcriptional activation include 
epigenetic mediators that induce chromatin remodel-
ling at AR response element sites [14, 15]. A key exam-
ple is the flavin-dependent nuclear amine oxidase LSD1 
[16]. LSD1 is a lysine demethylase which, dependant 
on context, can repress or activate transcription. The 
best characterised LSD1 substrates for demethylation 
are mono- and di-methylation at lysine 4 of histone H3 
(H3K4me1, H3K4me2) which are transcriptionally acti-
vating. LSD1 is a component of the CoREST transcrip-
tional co-repressor complex that also contains CtBP and 
histone deacetylase (HDAC) 1 and HDAC2. Within this 
complex, LSD1 demethylates H3K4me1 and H3K4me2, 
facilitating gene silencing in concert with HDAC activ-
ity [16, 17]. By contrast, LSD1 associates with the AR in 
human prostate cells to remove mono- and di-methyl 
marks at histone H3 lysine 9 (H3K9me1, H3K9me2) 
at ARE sites [14, 15]. In contrast to H3K4 methylation, 
H3K9 methylation is transcriptionally repressive and the 
AR co-regulator function of LSD1 facilitates AR depend-
ent transcriptional activation [14, 15]. LSD1 functions in 
concert with the histone demethylase lysine (K)-specific 
demethylase 4C, which demethylates H3K9me3 within 
AR activating complexes to promote AR mediated tran-
scription also [14, 15]. Cellular epigenetic status in favour 
of H3K9 demethylation by LSD1 over H3K4 demeth-
ylation is not fully elucidated but determined in part 
through protein kinase C beta I phosphorylation of his-
tone H3 threonine 6 [18]. Alternative splicing of LSD1 
may also impact on substrate specificities in some con-
texts [19].
LSD1 expression is increased in prostate cancer com-
pared with benign prostate and its expression correlates 
with higher Gleason score, risk of relapse and distant 
metastases, and reduced survival post prostatectomy 
[20, 21]. Histone marks consistent with LSD1 activity are 
altered in prostate cancer versus normal tissue (reduced 
H3K4me1, H3K9me2 and H3K9me3 marks) [22]. Taken 
together these data provide a rationale to develop LSD1 
inhibition as a strategy to attenuate AR signalling.
We and others have shown that chemical inhibition of 
LSD1 inhibits cell proliferation and AR signalling in pros-
tate cancer cells [14, 15, 23–25]. Validation of LSD1 as a 
potential therapeutic target in prostate cancer has been 
undertaken through LSD1 siRNA depletion experiments 
[14]. We hypothesised that LSD1 inhibition would also 
attenuate AR activation in models of CRPC driven by the 
AR-V7 splice variant.
Methods
Reagents and cell lines
Cell lines were maintained in Dulbecco’s Modified Eagle’s 
Medium (HEK293 cells; Sigma) or Roswell Park Memo-
rial Institute (RPMI) medium (LNCaP cells; Sigma) sup-
plemented with 10% fetal bovine serum (FBS) with 4 mM 
(HEK293) or 2  mM (LNCaP) l-glutamine and 1  mM 
pyruvate. For experiments, LNCaP cells were incubated 
for 24  h and then media was changed to RPMI-1640 
(phenol free; Life Technologies) supplemented, for the 
remainder of the experiment, with 10% charcoal stripped 
FBS (Life Technologies). Dihydrotestosterone (DHT) and 
5α-Androstan-17β-ol-3-one were from Sigma-Aldrich; 
LSD1 inhibitors LSD1-C76 and HCI-2509 were from 
Xcess Biosciences; enzalutamide and apalutamide were 
from Selleckchem. Chemical inhibitors of LSD1 were 
synthesised, and a separate publication will describe full 
details of the preparation.
In vitro LSD1 inhibition assay
IC50 values for LSD1 activity after chemical inhibition 
were measured as previously described [25]. Briefly, 
this involves incubation of the purified enzyme with an 
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H3K4me2 peptide substrate and measurement of by-
product  H2O2 using  AmplexRed® (Invitrogen).
Cell proliferation assays
Cell proliferation assays were performed by incubating 
cells in 96 well plates in RPMI complete medium. After 
24 h, different drugs or a DMSO control were added and 
analysis of proliferation was determined after 72 h using 
the CellTiter-Glo® 2.0 Assay (Promega) according to the 
manufacturer instructions. Luminescence was measured 
using a Varioskan Flash Multimode Reader (Thermo 
Scientific).
Immunoblotting
Cells were harvested and lysed by resuspension in pro-
tein sample buffer. DNA from samples was fragmented 
by sonication. Total protein from each sample was sepa-
rated using the Laemmli method [26]. After blocking, 
the membranes were immunoblotted overnight at 4  °C 
with primary antibodies to LSD1, PSA/KLK3, androgen 
receptor and cleaved PARP (Cell Signalling) and β-Actin 
(Sigma-Aldrich) as previously described [27].
CRISPR experiment
LSD1 knockout was undertaken in HEK293 cells accord-
ing to the protocol from Zhang et  al. [28]. Briefly, 
HEK293 cells were transfected with the Cas9 expressing 
vector pSpCas9(BB)-2A-GFP (Addgene) with a guide 
sequence targeting the ATG for KDM1A (LSD1). For the 
selection of the guide sequence oligonucleotide we used 
an online tool for CRISPR design (http://crisp r.mit.edu/). 
Guide sequence oligonucleotides were, top 5′ caccgTGT 
GTT TTG ATC GGG TGT TC 3′ and bottom 5′ aaacGAA 
CAC CCG ATC AAA ACA CAc 3′.
Luciferase reporter assays
Luciferase assays were performed using a vector (pARE-
Luc) with the firefly luciferase gene under the control 
of the androgen receptor response element (ARE) in 
HEK293 cells co-transfected with peAR-Wt and peAR-
V7 plasmids and with a renilla luciferase vector used as 
a transfection efficiency control as previously described 
[29, 30]. Briefly, HEK293 cells were transfected with 
Fugene HD (Promega) using a 9:1 ratio of AR:ARE vec-
tors (1 µg DNA) along with 5 ng of a renilla control vec-
tor. After 30 h, cells were treated with chemical inhibitors 
according to the experimental requirements and then 
firefly and renilla luciferase activity were measured using 
the Dual-Luciferase® Reporter Assay System (Promega) 
in a Varioskan™ Flash Multimode Reader (Thermo Sci-
entific). All results show firefly luciferase activity nor-
malised to renilla luciferase activity to control for 
transfection efficiency.
Chromatin immunoprecipitation (CHIP) assay
CHIP assays were performed using the ChIP-IT® High 
Sensitivity kit (Active Motif ) according to the manufac-
turer’s instructions. Immunoprecipitation of the chro-
matin bound DNA was performed using the following 
antibodies from Active Motif: Histone H3 K9me3, His-
tone H3, Histone H3 K9me2, Histone H3K9me1. The 
ChIP-IT® Control Kit, Human was used with these 
assays as a control.
Quantitative real‑time PCR
Total mRNA extraction was performed using the 
RNAeasy kit (Qiagen) according to the manufacturer’s 
instructions. Contaminating DNA was digested using 
RQ1 DNAse (Promega). Synthesis of cDNA was per-
formed using M-MLV Reverse Transcriptase (Promega) 
according to the manufacturer’s instructions. For qRT-
PCR we used the  TaqMan® Universal PCR Master Mix, 
No  AmpErase® UNG (ThermoFischer Scientific) and 
 TaqMan® Gene Expression Assays probes for KLK3 
(PSA) and for the reference gene GAPDH. Assays were 
performed in an Applied Biosystems 7500 Real Time 
PCR System. Quantification of mRNA expression levels 
was performed using the  2−∆∆C(T) method as described 
[31].
Results
Chemical inhibition of LSD1 inhibits activity 
of the androgen receptor
We first validated the impact of LSD1 chemical inhi-
bition on wild type androgen receptor transcriptional 
activation. We investigated the effects of the LSD1 
inhibitor tranylcypromine (1, Additional file  1: Figure 
S1) which is currently under investigation in clinical 
trials for acute myeloid leukaemia (http://www.clini 
caltr ials.gov) and a set of five second-generation tra-
nylcypromine analogues (2–6, Additional file  1: Fig-
ure S1) with improved target affinity in biochemical 
enzyme assays. Each of these compounds were shown 
to inhibit both in vitro activity of LSD1 and cell prolif-
eration in LNCaP prostate cancer cells (Table 1, Addi-
tional file  1: Figure S2, Figure S3) but with many fold 
increase in potency over the tranylcypromine base 
compound. LSD1 chemical inhibition reversed DHT 
induced loss of histone H3 K9 mono-methylation in 
LNCaP prostate cancer cells in CHIP assays (Fig. 1). We 
also demonstrated reduction of AR and LSD1 protein 
expression and of the AR transcriptional target PSA in 
LNCaP cells, together with evidence of PARP cleavage 
in response to LSD1 inhibition (Fig. 2).
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LSD1 chemical inhibition attenuates AR‑V7 splice variant 
activation
AR-V7 and other AR splice variant forms are strongly 
implicated in hormonal therapy resistance and may 
contribute to some forms of castration resistant pros-
tate cancer [7, 8]. To explore the impact of LSD1 on 
AR-V7 activity, we initially utilised a luciferase reporter 
assay system to measure ARE activation in HEK-293 
cells through co-transfection of the AR with either 
wild type (WT) or V7 splice variant forms. Within 
this model system, we first confirmed that AR-WT 
activation is inhibited by the established AR antago-
nists enzalutamide [2, 5] and apalutamide [32, 33] but 
that the AR-V7 splice variant, by virtue of constitutive 
activation and loss of the binding site for either drug, 
demonstrates resistance to these agents (Additional 
file  1: Figure S4). Having confirmed the anticipated 
functional characteristics of this system we then dem-
onstrated that partial inhibition of AR-V7 constitutive 
activation is seen upon chemical inhibition of LSD1 
(Fig. 3).
LSD1 depletion attenuates both AR‑WT and AR splice 
variant activation
To validate evidence that LSD1 contributes to the activ-
ity of AR splice variant forms we undertook experiments 
to deplete LSD1 expression in HEK-293 cells followed by 
co-transfection of either AR-WT or splice variant forms 
in ARE luciferase reporter experiments. Depletion of 
LSD1 (by CRISPR; Additional file 1: Figure S5) resulted 
in partial inhibition of AR activity in this model for both 
the AR-WT and the AR-V7 splice variant and also for a 
further, constitutively active, AR C-terminal truncated 
splice variant Q640X (Fig. 4) [29].
We next turned to a prostate cancer cell line model for 
AR-V7 activation through transfection of an AR-WT or 
AR-V7 expression construct into the LNCaP cell line. 
In this model, chemical inhibition of LSD1 resulted in 
depletion of AR-WT and LSD1, although not AR-V7 in 
this model, and also the AR transcriptional target PSA 
(Fig. 5).
LSD1 inhibition depletes AR activity in prostate cancer 
cells expression endogenous AR‑V7
Finally we utilised the 22Rv1 prostate cancer cell line 
to represent a CRPC model with high AR activity and 
endogenous expression of both the AR full length and V7 
forms [34]. In 22Rv1 cells we showed reduced expression 
of both AR-WT, AR-V7 and LSD1 and also depletion of 
PSA RNA levels on exposure to chemical inhibition of 
LSD1 (Fig. 6).
Discussion
Castration resistant prostate cancer is a challenging dis-
ease. Although there have been significant advances in 
new therapeutic options, including hormonal therapy, 
chemotherapy, systemic radioisotope therapy and immu-
notherapy, the disease remains highly lethal [2–5, 33, 35–
37]. In fact, CRPC normally remains critically dependent 
on AR signalling, even following acquired resistance to 
hormonal interventions such as enzalutamide, apaluta-
mide and abiraterone [7, 8]. The mechanisms underlying 
castration resistance commonly relate to the AR itself 
through receptor amplification, activating point muta-
tions and constitutively active truncating splice vari-
ants of which the AR-V7 splice variant is a key example. 
One strategy to develop novel approaches to CRPC is 
Table 1 IC50 and   LD50 values for  LSD1 inhibitor 
compounds for in vitro LSD1 inhibition assays and LNCaP 
prostate cancer cell proliferation assays respectively
Data represent mean values ± standard deviation (SD), as indicated, for a 
minimum of three experiments in each case
Compound LSD1 inhibition Cell proliferation
IC50 mean 
(nM)
SD (nM) LD50 mean 
(μM)
SD (μM)
Tranylcy-
promine (1)
57,980.0 5922.9 2235.0 173.6
2 4389.0 157.9 136.3 1.7
3 1520.5 890.3 605.9 90.4
4 259.3 22.8 224.9 27.9
5 269.4 35.7 712.4 48.5
6 221.6 26.7 183.9 19.6
LSD1-C76 527.0 9.0 85.1 9.5
ARE III (Enhancer)
Acn
IP Histone H3
LNCAP CSS Media LNCAP CSS Media
DMSO D D+C76 DMSO D  D+C76
IP Histone H3 K9 
Monomethylated
Fig. 1 CHIP analysis of LNCaP cells treated with the LSD1 inhibitor 
LSD1-C76. LNCaP cells were incubated in media with charcoal 
stripped serum (CSS) for 24 h prior to addition of dihydrotestosterone 
(D, 1 nM) ± LSD1-C76 (C76, 250 μM) for 24 h. CHIP was performed 
using histone H3 and histone H3 K9 mono-methylated antibodies. 
Precipitated chromatin was amplified using primers flanking the 
enhancer region (ARE III) of the PSA gene or actin gene promoter [14]. 
DMSO dimethyl sulfoxide solvent control
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therefore to target abnormal forms of the AR, including 
constitutively active splice variants, of which AR-V7 is 
the most frequently relevant form [7, 8].
Epigenetic therapeutic approaches remain experimen-
tal in prostate cancer. However, evidence exists for a vari-
ety of epigenetic mechanisms driving prostate cancer 
development, disease progression and aggressiveness, 
and transition to a CRPC phenotype. Relevant epigenetic 
aberrations include silencing of tumour suppressor genes 
by promoter hypermethylation, aberrant expression of 
histone modulating proteins, and DNA hypomethylation 
[38]. Potential approaches to target these are therefore of 
interest. DNA methyltransferase inhibition and histone 
deacetylase inhibition have received the most attention 
although translation through to clinical benefit remains 
to be established, perhaps partly due to a lack of com-
panion predictive biomarkers for these approaches [38]. 
LSD1 has been shown to attenuate wild type AR activ-
ity and drive progression of the disease to more advanced 
clinical states [15, 20–24, 38]. We therefore sought to test 
whether this would extend to an impact on the function 
of AR-V7 as a key driver of many cases of CRPC and hor-
monal therapy resistance [7, 8].
We have established, in a variety of models, that LSD1 
inhibition will attenuate signalling through not just the 
WT form of the receptor but also the ligand independ-
ent constitutively active AR-V7 form. Evidence for our 
ability to target the receptor with chemical inhibition 
was validated through use of knockdown experiments 
to deplete LSD1 expression. In addition we have dem-
onstrated this in both a HEK293 co-transfection model 
to facilitate isolation of this phenomenon to AR-V7 or 
AR-WT separately, as well as in prostate cancer cell 
line models for dual V7 and WT expression through 
either forced expression (LNCaP cells) or endogenous 
expression (22Rv1 cells). We therefore propose that the 
impact of LSD1 on the androgen receptor is likely not 
lost by transition to a castration resistant phenotype 
where this arises through AR-V7 activity and regard-
less of the WT/V7 co-expression status. This would 
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Fig. 2 Chemical inhibition of LSD1 reduces AR, PSA and LSD1 expression and induces PARP cleavage. a Western blot analysis of the indicated 
targets in LNCaP prostate cancer cells, grown in charcoal stripped media for 24 h before exposure to dihydrotestosterone (DHT, 1 nM) or LSD1-C76 
(250 μM) for 24 or 48 h as indicated. b–e Quantification of PSA (b), LSD1 (c), cPARP (d) and AR-WT (e) protein levels by densitometry analysis and 
normalized to β-actin. Western blots are representative of two independent experiments. P values were derived using 2 Way ANOVA multiple 
comparisons test. cPARP, cleaved PARP; ** and ***P < 0.005 and P < 0.001 respectively
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imply that AR-V7 retains a requirement for complex 
formation with LSD1, for functional activation. Having 
established that AR-V7 driven prostate cancer remains 
susceptible to targeting of LSD1, at least in the model 
systems used here, it will be important to dissect the 
molecular interaction between chemical LSD1 inhibi-
tion and an LSD1:AR interaction. Proper understand-
ing of the molecular basis for a therapeutic effect will 
be critical to facilitate exploitation of this strategy. In 
addition, we fully acknowledge that LSD1 inhibition 
might function as a therapeutic strategy through other 
mechanisms beyond targeting of AR-WT and AR-V7.
Our results would suggest broadly that depletion of 
LSD1 activity was able to reduce AR-V7 activation by 
about 50% in most of the experimental models that 
we utilised. This was seen in LSD1 knockdown mod-
els and so implies that this may be more than a simple 
‘drug potency’ issue. It is likely that other epigenetic 
influences on AR activation remain relevant and thus 
combinatorial approaches may be required for opti-
mal suppression of AR function [38]. To what degree 
a greater impact on AR signalling, either through the 
wild type or V7 splice variant forms of the AR will be 
required for therapeutic efficacy remains to be deter-
mined. Our work has shown that reduced LSD1 activ-
ity is effective in attenuating signalling through the AR 
Q640X splice variant in addition to AR-V7 suggesting 
that this experimental approach might be considered 
more widely than just ‘AR-V7 positive’ CRPC. CRPC 
driven through other AR activating mechanisms, such 
as activating point mutations, AR amplification, AR 
phosphorylation or AR methylation should be investi-
gated also.
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Fig. 3 LSD1 chemical inhibition depletes AR response element 
activation through the AR-V7 splice variant. Luciferase reporter assay 
of AR response element (ARE) promotor activation in HEK293 cells 
co-transfected, 24 h after seeding as indicated, with either AR-WT or 
AR-V7 expression vectors, and incubated 24 h later as indicated with 
dihydrotestosterone (DHT, 1 nM), LSD1-C76 (250 μM) or HCl-2509 
(5 μM) or DMSO solvent control and then analysed at 18 h. Samples 
were normalized against the AR-WT DMSO treated samples. Data are 
mean values ± standard deviation from 4 separate experiments each 
with triplicate determinations. P values were derived using a two-way 
ANOVA for comparison followed by Tukey’s multiple comparison post 
hoc tests. AR androgen receptor; WT wild type; ****P < 0.0001
AR V7 AR Q640XAR WT
0
50
100
* * * *
0
50
100
****
0
50
100
* * * * LSD1
Acn
WT KO
W
T
W
T
W
T
KOKO KO
%
 lu
ci
fe
ra
se
 e
xp
re
ss
io
n
%
 lu
ci
fe
ra
se
 e
xp
re
ss
io
n
%
 lu
ci
fe
ra
se
 e
xp
re
ss
io
n
a b
Fig. 4 AR-V7 splice variant activation is attenuated by LSD1 depletion. a Luciferase androgen response element (ARE) reporter assays in HEK293 
cells with (KO) or without (C) stable depletion of LSD1 (by CRISPR) followed by transient co-transfection with an ARE luciferase reporter construct 
and either AR-WT, AR-V7 or AR Q640X expression vectors as indicated. In the cells transfected with AR-WT, dihydrotestosterone (1 nM) was added 
for 18 h. Samples were normalized against LSD1 WT DMSO treated samples for the respective AR-WT of AR variant form transfected. Data are 
mean ± SD (n = 3). P values were derived using a two-way ANOVA for comparison followed by Tukey’s multiple comparison post hoc tests. (Controls 
without transfection of either the AR or an AR variant produced no ARE luciferase signal in these experiments). b Western blot of HEK293 cell LSD1 
expression with (KO) or without (WT) stable depletion of LSD1. ****P < 0.0001
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Conclusions
AR-V7 splice variant models of CRPC are amenable to 
therapeutic targeting through LSD1 inhibition. This raises 
the opportunity to develop this therapeutic strategy further.
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derived using a two-way ANOVA for comparison followed by Tukey’s mul-
tiple comparison post hoc tests. (B) Western blot to confirm AR expression 
following transfection of either the WT or V7 or Q640X splice variant forms 
or an untransfected sample, as indicated, in HEK293 cells. ****, P < 0.0001; 
ns, non-significant; NT, non-transfected. Figure S5. Western blot analysis 
of LSD1 expression for different clones obtained after the CRISPR experi-
ment. (A) immunoblot for the N-terminus of human LSD1. (B) immunoblot 
for the C-terminus of human LSD1. Actin expression is shown as a protein 
loading control.
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Fig. 5 Chemical inhibition of LSD1 reduces PSA expression driven 
by AR-V7. a Western blot analysis of AR, LSD1 and PSA expression in 
LNCaP cells transfected with either the AR-WT or the AR-V7 splice 
variant as indicated. LNCaP cells were incubated in CSS-media 
for 24 h prior to transfection and after 24 h LSD1-C76 (250 μM) or 
DMSO solvent control were added for 18 h. b Quantification of 
PSA expression in three independent experiments. PSA levels were 
normalized against the DMSO treated samples. P values were derived 
using an unpaired t test with Welch’s correction. ***P < 0.05
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Fig. 6 Chemical inhibition of LSD1 depletes AR activity in an AR-V7 
expressing 22Rv1 prostate cancer cells. 22Rv1 cells, expressing 
both endogenous AR-WT and V7 splice variants, were incubated 
in CSS-media for 24 h prior to adding dihydrotestosterone (DHT, 
1 nM) and LSD1-C76 (250 μM) for 18 h as indicated (or DMSO 
solvent control). a Western blot analysis of AR and LSD1 expression. 
b PSA mRNA expression determined by qPCR in three independent 
experiments. P values were derived using an unpaired t test with 
Welch’s correction. ****P < 0.05
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